EI
KRYS icon

Ellevest Inc’s Krystal Biotech KRYS Stock Holding History

Ellevest Inc’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-150
Closed -$12K – 1034
2023
Q1 		$12K Buy
150
+20
+15% +$1.57K ﹤0.01% 989
2022
Q4 		$10.3K Sell
130
-8
-6% -$594 ﹤0.01% 1018
2022
Q3 		$10K Buy
138
+96
+229% +$6.94K ﹤0.01% 995
2022
Q2 		$3K Buy
+42
New +$2.61K ﹤0.01% 1099

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ellevest Inc's KRYS Position: Q2 2023 in Review

Ellevest Inc sold out of Krystal Biotech (KRYS) in Q2 2023, closing a stake of 150 shares — an estimated $12K sold.

Ellevest Inc first reported a position in KRYS in Q2 2022 and held it in 4 quarters. The position peaked at $12K in Q1 2023. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

  • Ellevest Inc reported no remaining Krystal Biotech position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 150 Krystal Biotech shares in Q2 2023, an estimated $12K.
  • Ellevest Inc first reported a position in Krystal Biotech in Q2 2022 and held it in 4 quarters.
  • Ellevest Inc's Krystal Biotech position peaked at $12K in Q1 2023.
  • 183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.